A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Safety and Efficacy of OBI-858 in Patients with Moderate-to-Severe Glabellar Lines - Scorecard - MDSpire
Advertisement
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Safety and Efficacy of OBI-858 in Patients with Moderate-to-Severe Glabellar Lines
Clinical Scorecard: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Safety and Efficacy of OBI-858 in Patients with Moderate-to-Severe Glabellar Lines
At a Glance
Category
Detail
Condition
Key Mechanisms
OBI-858 is a 760 kDa botulinum toxin type A complex that inhibits acetylcholine release at the neuromuscular junction, targeting wrinkle reduction.
Target Population
Care Setting
Key Highlights
OBI-858 at 20U showed significantly better wrinkle reduction than 10U or placebo (p-value needed).
Effects of OBI-858 lasted up to 24 weeks with sustained patient satisfaction.
Guideline-Based Recommendations
Diagnosis
Management
Administer OBI-858 intramuscularly at five sites in the glabellar region, with a recommended dose of 20U.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
OBI-858 demonstrates longer duration of effect compared to existing formulations, with a noted efficacy lasting up to 24 weeks.
Clinical Best Practices
Monitor for adverse effects such as localized pain, swelling, or allergic reactions during follow-up visits.
